Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Bikash Dangi, Nadezhda Y. Davydova, Nikita E. Vavilov, Victor G. Zgoda & Dmitri R. Davydov. (2020) Nonadditivity in human microsomal drug metabolism revealed in a study with coumarin 152, a polyspecific cytochrome P450 substrate. Xenobiotica 50:12, pages 1393-1405.
Read now
Read now
Kristyna Krasulova, Michal Siller, Ondrej Holas, Zdenek Dvorak & Pavel Anzenbacher. (2016) Enantiospecific effects of chiral drugs on cytochrome P450 inhibition in vitro. Xenobiotica 46:4, pages 315-324.
Read now
Read now
David J. Greenblatt, Yanli Zhao, Michael J. Hanley, Chunxian Chen, Jerold S. Harmatz, Paul F. Cancalon & Frederick G. Gmitter$suffix/text()$suffix/text(). (2012) Mechanism-based inhibition of human Cytochrome P450-3A activity by grapefruit hybrids having low furanocoumarin content. Xenobiotica 42:12, pages 1163-1169.
Read now
Read now
Dmitri R Davydov. (2011) Microsomal monooxygenase as a multienzyme system: the role of P450-P450 interactions. Expert Opinion on Drug Metabolism & Toxicology 7:5, pages 543-558.
Read now
Read now
Articles from other publishers (26)
Yuki Yamaguchi, Takeshi Akiyoshi, Go Kawamura, Ayuko Imaoka, Mitsue Miyazaki, F. Peter Guengerich, Katsunori Nakamura, Koujirou Yamamoto & Hisakazu Ohtani. (2021) Comparison of the inhibitory effects of azole antifungals on cytochrome P450 3A4 genetic variants. Drug Metabolism and Pharmacokinetics 38, pages 100384.
Crossref
Crossref
Manman Zhao, Jiaqi Mi, Baolian Wang, Qiong Xiao, Yulin Tian, Jinping Hu & Yan Li. (2021) Insights into the metabolic characteristics of aminopropanediol analogues of SYLs as S1P1 modulators: from structure to metabolism. European Journal of Pharmaceutical Sciences 158, pages 105608.
Crossref
Crossref
F. Peter Guengerich, Kevin D. McCarty & Jesse G. Chapman. (2021) Kinetics of cytochrome P450 3A4 inhibition by heterocyclic drugs defines a general sequential multistep binding process. Journal of Biological Chemistry 296, pages 100223.
Crossref
Crossref
F. Peter Guengerich. (2020) A history of the roles of cytochrome P450 enzymes in the toxicity of drugs. Toxicological Research 37:1, pages 1-23.
Crossref
Crossref
Christopher R. Gibson, Ying-Hong Wang, Ninad Varkhede & Bennett Ma. 2021. Enzyme Kinetics in Drug Metabolism. Enzyme Kinetics in Drug Metabolism
443
479
.
Jeffry Adiwidjaja, Alan V. Boddy & Andrew J. McLachlan. (2020)
Potential for pharmacokinetic interactions between
Schisandra sphenanthera
and bosutinib, but not imatinib: in vitro metabolism study combined with a physiologically‐based pharmacokinetic modelling approach
. British Journal of Clinical Pharmacology 86:10, pages 2080-2094.
Crossref
Crossref
Dominique A. Garrison, Zahra Talebi, Eric D. Eisenmann, Alex Sparreboom & Sharyn D. Baker. (2020) Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors. Pharmaceutics 12:9, pages 856.
Crossref
Crossref
Jasleen K. Sodhi, Shuaibing Liu & Leslie Z. Benet. (2020) Challenging the Relevance of Unbound Tissue-to-Blood Partition Coefficient (Kpuu) on Prediction of Drug-Drug Interactions. Pharmaceutical Research 37:4.
Crossref
Crossref
David J. Greenblatt & Gerd Mikus. (2019) Ketoconazole and Liver Injury: A Five-Year Update. Clinical Pharmacology in Drug Development 8:1, pages 6-8.
Crossref
Crossref
Sara Algeelani, Dalal Alkhelb & David J. Greenblatt. (2018)
Inhibitory effects of sulfonylureas and non-steroidal anti-inflammatory drugs on
in vitro
metabolism of canagliflozin in human liver microsomes
. Biopharmaceutics & Drug Disposition 39:3, pages 135-142.
Crossref
Crossref
Katsumi Iga & Akiko Kiriyama. (2017) Simulations of Cytochrome P450 3A4-Mediated Drug-Drug Interactions by Simple Two-Compartment Model-Assisted Static Method. Journal of Pharmaceutical Sciences 106:5, pages 1426-1438.
Crossref
Crossref
Katsumi Iga & Akiko Kiriyama. (2017) Usefulness of Two-Compartment Model-Assisted and Static Overall Inhibitory-Activity Method for Prediction of Drug–Drug Interaction. Biological & Pharmaceutical Bulletin Biological and Pharmaceutical Bulletin 40:12, pages 2024-2037.
Crossref
Crossref
David J. Greenblatt & Jerold S. Harmatz. (2015) Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies. British Journal of Clinical Pharmacology 80:3, pages 342-350.
Crossref
Crossref
H. Karl Greenblatt & David J. Greenblatt. (2014) Liver injury associated with ketoconazole: Review of the published evidence. The Journal of Clinical Pharmacology 54:12, pages 1321-1329.
Crossref
Crossref
Aneta Novotná, Kristýna Krasulová, Iveta Bartoňková, Martina Korhoňová, Petr Bachleda, Pavel Anzenbacher & Zdeněk Dvořák. (2014) Dual Effects of Ketoconazole cis-Enantiomers on CYP3A4 in Human Hepatocytes and HepG2 Cells. PLoS ONE 9:10, pages e111286.
Crossref
Crossref
D J Greenblatt. (2014) In Vitro Prediction of Clinical Drug Interactions With CYP3A Substrates: We Are Not There Yet. Clinical Pharmacology & Therapeutics 95:2, pages 133-135.
Crossref
Crossref
Ying-Hong Wang & Christopher R. Gibson. 2014. Enzyme Kinetics in Drug Metabolism. Enzyme Kinetics in Drug Metabolism
337
362
.
David J. Greenblatt. (2014) The ketoconazole legacy. Clinical Pharmacology in Drug Development 3:1, pages 1-3.
Crossref
Crossref
Sara K. Quinney, Shawn Knopp, Chien Chang, Stephen D. Hall & Lang Li. (2013)
Integration of
In Vitro
Binding Mechanism Into the Semiphysiologically Based Pharmacokinetic Interaction Model Between Ketoconazole and Midazolam
. CPT: Pharmacometrics & Systems Pharmacology 2:9, pages 1-8.
Crossref
Crossref
C. Lau, K.D. Mooiman, R.F. Maas-Bakker, J.H. Beijnen, J.H.M. Schellens & I. Meijerman. (2013) Effect of Chinese herbs on CYP3A4 activity and expression in vitro. Journal of Ethnopharmacology 149:2, pages 543-549.
Crossref
Crossref
Sebastian Frechen, Lisa Junge, Teijo I. Saari, Ahmed Abbas Suleiman, Dennis Rokitta, Pertti J. Neuvonen, Klaus T. Olkkola & Uwe Fuhr. (2013) A Semiphysiological Population Pharmacokinetic Model for Dynamic Inhibition of Liver and Gut Wall Cytochrome P450 3A by Voriconazole. Clinical Pharmacokinetics 52:9, pages 763-781.
Crossref
Crossref
Guohua An, Wei Liu, David A. Katz, Gerard Marek, Walid Awni & Sandeep Dutta. (2013)
Effect of Ketoconazole on the Pharmacokinetics of the 11
β
-Hydroxysteroid Dehydrogenase Type 1 Inhibitor ABT-384 and Its Two Active Metabolites in Healthy Volunteers: Population Analysis of Data from a Drug-Drug Interaction Study
. Drug Metabolism and Disposition 41:5, pages 1035-1045.
Crossref
Crossref
Howard J. Burt, Henry Pertinez, Carolina Säll, Claire Collins, Ruth Hyland, J. Brian Houston & Aleksandra Galetin. (2012) Progress Curve Mechanistic Modeling Approach for Assessing Time-Dependent Inhibition of CYP3A4. Drug Metabolism and Disposition 40:9, pages 1658-1667.
Crossref
Crossref
Sussan Ghassabian, Tristan Rawling, Fanfan Zhou, Munikumar R. Doddareddy, Bruce N. Tattam, David E. Hibbs, Robert J. Edwards, Pei H. Cui & Michael Murray. (2012) Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites. Biochemical Pharmacology 84:2, pages 215-223.
Crossref
Crossref
V. Zlabek & G. Zamaratskaia. (2012) Comparison of three fluorescent CYP3A substrates in two vertebrate models: pig and Atlantic salmon. Animal 6:4, pages 633-640.
Crossref
Crossref
David J Greenblatt, Yanli Zhao, Karthik Venkatakrishnan, Su X Duan, Jerold S Harmatz, Sarah J Parent, Michael H Court & Lisa L von Moltke. (2011) Mechanism of cytochrome P450-3A inhibition by ketoconazole. Journal of Pharmacy and Pharmacology 63:2, pages 214-221.
Crossref
Crossref